OnCo
ideasIdea

Linked human organ chips to predict side effects before people are dosed

Damage to the lungs, heart or liver is a common reason cancer drugs fail. Connected chips of human tissue may spot this earlier than animal tests.

Interstitial lung disease with ADCs, cardiotoxicity with HER2 agents and hepatotoxicity with several classes are poorly predicted by rodents. Coupled microphysiological systems with human lung, heart, liver and kidney compartments and shared circulation can measure organ-specific injury from a candidate at clinically relevant exposures. US legislation now allows non-animal methods to support investigational new drug applications, giving a regulatory route.

Hypothesis
A multi-organ chip panel correctly identifies the organ of clinical dose-limiting toxicity for the majority of a retrospective set of ADCs with known human toxicity profiles.
Rationale
ADC toxicity is frequently payload- and off-target-driven in human-specific ways; the chips are human by construction, and the retrospective validation set already exists.
What would test it
Blinded retrospective study across 15 ADCs and kinase inhibitors with known clinical toxicity, scoring organ prediction accuracy against animal study predictions.
Maturity
preclinical evidence
Who has to act
engineering
Cost to try
Medium ($1M to $50M)
Years to first evidence
4
Bottlenecks it attacks

Connected

6top